natgillin/translations-raw huggingface dataset:
Brimica Genuair improved daily symptoms of COPD such as ‘breathlessness’, ‘chest symptoms’, ‘cough and sputum’ (assessed by E-RS total score) as well as overall night-time symptoms, overall early morning symptoms and symptoms limiting early morning activities compared to placebo, aclidinium and formoterol but the improvements were not always statistically significant.
Brimica Genuair je poboljšao dnevne simptome KOPB-a kao što su 'nedostatak zraka', 'simptomi u prsištu', 'kašalj i ispljuvak' (procijenjeno prema E-RS ukupnom rezultatu), kao i ukupne noćne i ukupne ranojutarnje simptome, te simptome koji ograničavaju ranojutarnje aktivnosti u usporedbi s placebom, aklidinijem i formoterolom, no poboljšanja nisu uvijek bila statistički značajna.
Brimica Genuair is a white or almost white powder.
Brimica Genuair je bijeli ili gotovo bijeli prašak.
Brimica Genuair is not for use in children or adolescents below 18 years of age.
Brimica Genuair nije namijenjen djeci i adolescentima mlađim od 18 godina.
Brimica Genuair should not be used in asthma; clinical studies of Brimica Genuair in asthma have not been conducted.
Brimica Genuair se ne smije koristiti kod astme; nisu provedena klinička ispitivanja Brimica Genuaira kod astme.
Brimica Genuair should only be used during pregnancy if the expected benefits outweigh the potential risks.
Brimica Genuair se smije koristiti tijekom trudnoće samo ako je očekivana korist veća od potencijalnih rizika.
Brimonidine did not present any special reproductive or developmental hazard in animal species.
Brimonidin nije pokazao nikakve posebne rizike za razmnožavanje ili razvoj životinjskih vrsta.
Brimonidine is extensively metabolised by the liver.
Brimonidin se ekstenzivno metabolizira u jetri.
Brimonidine is extensively metabolized by hepatic aldehyde oxidase with formation of 2-oxobrimonidine, 3- oxobrimonidine and 2,3-dioxobrimonidine being the major metabolites.
Brimonidin se opsežno metabolizira jetrenom aldehid oksidazom, a glavni su mu metaboliti 2- oksobrimonidin, 3-oksobrimonidin i 2,3-dioksobrimonidin.
Brimonidine tartrate may cause ocular allergic reactions.
Brimonidin tartarat može uzrokovati okularne alergijske reakcije.
BRINAVESS cannot be recommended in patients previously administered intravenous AADs (class I and III) 4-24 hours prior to vernakalant due to lack of data.
BRINAVESS se zbog nedostatka podataka ne može preporučiti za bolesnike koji su 4 do 24 sata prije primjene vernakalanta intravenski primili antiaritmike (skupine I i III).
BRINAVESS cannot be recommended in patients previously administered intravenous AADs (class I and III) 4-24 hours prior to vernakalant, due to lack of data.
BRINAVESS se zbog nedostatka podataka ne može preporučiti za bolesnike koji su 4 do 24 sata prije primjene vernakalanta intravenski primili antiaritmike (skupine I i III).
BRINAVESS contains the active substance vernakalant hydrochloride.
BRINAVESS sadrži djelatnu tvar vernakalantklorid.
BRINAVESS has a minor to moderate influence on the ability to drive and use machines.
BRINAVESS malo do umjereno utječe na sposobnost upravljanja vozilima i rada sa strojevima.
BRINAVESS has been administered to patients with an uncorrected QT less than 440 msec without an increased risk of torsade de pointes.
BRINAVESS se primjenjivao u bolesnika s nekorigiranim QT-intervalom kraćim od 440 ms bez povećanja rizika za pojavu torsade de pointes.
BRINAVESS is dosed by patient body weight, with a maximum calculated dose based upon 113 kg.
Doza lijeka BRINAVESS određuje se prema tjelesnoj težini bolesnika, a najviša je doza izračunata na temelju težine od 113 kg.
BRINAVESS may be available in different vial sizes (available vial sizes to be inserted locally).
BRINAVESS može biti dostupan u bočicama različite veličine (dostupne veličine bočica unijeti lokalno).
BRINAVESS must not be administered in patients who received intravenous AADs (class I and III) within 4 hours prior to vernakalant (see section 4.3).
BRINAVESS se ne smije primijeniti u bolesnika koji su intravenski primili antiaritmike (skupine I i III) unutar 4 sata prije primjene vernakalanta (vidjeti dio 4.3).
BRINAVESS should be administered in a monitored clinical setting appropriate for cardioversion by a well-qualified healthcare professional.
BRINAVESS mora primijeniti dobro osposobljen zdravstveni djelatnik u kontroliranim kliničkim uvjetima u kojima se može provesti kardioverzija.
BRINAVESS should be used with caution in patients on oral AADs (class I and III), due to limited experience.
Zbog ograničenog iskustva BRINAVESS treba primjenjivati uz oprez u bolesnika koji uzimaju oralne antiaritmike (skupine I i III).
BRINAVESS was not found to be effective in converting typical primary atrial flutter to sinus rhythm.
Pokazalo se da BRINAVESS nije učinkovit u konverziji tipične primarne undulacije atrija u sinusni ritam.
BRINAVESS was shown to provide relief of atrial fibrillation symptoms consistent with conversion to sinus rhythm.
Utvrđeno je da BRINAVESS olakšava simptome fibrilacije atrija sukladno konverziji u sinusni ritam.
BRINAVESS will be diluted before being given to you.
Prije nego što ga primite, BRINAVESS će biti razrijeđen.
BRINAVESS will be given to you by a health care professional.
BRINAVESS će Vam dati zdravstveni djelatnik.
Bring it out half an hour before injecting.
Izvadite pola sata prije injiciranja.
Bring NovoRapid PumpCart to room temperature.
NovoRapid PumpCart treba postići sobnu temperaturu.
Bring the bottle tip close to the eye.
Prinesite bočicu blizu oku.
Bring the bottle tip close to the eye.
Vrh boce prinesite oku.
Bring the bottle tip close to the eye.
Vrh bočice približite oku.
Bring the bottle tip close to the eye.
Vrh bočice prinesite blizu oku.
Bring the bottle tip close to the eye.
Vrh kapaljke bočice približite oku.
Bring the bottle tip close to the eye.
Vrh kapaljke približite oku.
Bring the container tip close to the eye.
Primaknite vrh spremnika oku.
Bring the OBIZUR powder vial and pre-filled diluent solvent syringe to room temperature.
Bočica praška OBIZUR i napunjena štrcaljka otapala trebaju dosegnuti sobnu temperaturu.
Bring the powder and solvent vials to a temperature not above 25°C, by holding them in the hands until they feel as warm as your hands.
Pustite da temperatura bočica s praškom i otapalom dosegnu temperaturu ne višu od 25°C, držeći ih u rukama sve dok ne osjetite da su tople kao i Vaše ruke.
Bring the syringe to eye level.
Podignite štrcaljku do razine očiju.
Bring the syringe to the correct dose needed.
Istisnite višak, kako bi u štrcaljki ostala ispravna doza.
Bring the two vials to a temperature between 15°C and 25°C.
Zagrijte dvije bočice na temperaturu između 15 °C i 25 °C.
Bring the vial and the pre-filled syringe to room temperature (not above 37°C).
Bočica i napunjena štrcaljka trebaju postići sobnu temperaturu (ne iznad 37°C).
Bring the vial and the prefilled syringe to room temperature.
Bočica i napunjena štrcaljka trebaju postići sobnu temperaturu.
Brintellix 10 mg film-coated tablets vortioxetine
Brintellix 10 mg filmom obložene tablete vortioxetinum
Brintellix 10 mg Tablet vortioxetine
Brintellix 10 mg tableta vortioxetinum
Brintellix 15 mg Tablet vortioxetine
Brintellix 15 mg tableta vortioxetinum
Brintellix 20 mg film-coated tablets vortioxetine
Brintellix 20 mg filmom obložene tablete vortioxetinum
Brintellix 20 mg Tablet vortioxetine
Brintellix 20 mg tableta vortioxetinum
Brintellix 20 mg/ml
Brintellix 20 mg
Brintellix 20 mg/ml oral drops, solution
Brintellix 20 mg/ml oralne kapi, otopina
Brintellix 20 mg/ml oral drops, solution vortioxetine
Brintellix 20 mg/ ml oralne kapi, otopina vortioxetinum
Brintellix 5 mg film-coated tablets
Brintellix 5 mg filmom obložene tablete Jezgra tablete
Brintellix 5 mg film-coated tablets vortioxetine
Brintellix 5 mg filmom obložene tablete vortioxetinum
Brintellix 5 mg Tablet vortioxetine
Brintellix 5 mg tableta vortioxetinum
Brintellix Brintellix
EU/1/13/891/005
Brintellix film-coated tablets 10 mg are available in blister packs of 7, 14, 28, 56, 56 x 1, 98, 98 x 1,
Brintellix filmom obložene tablete 10 mg dostupne su u blister pakiranjima od 7, 14, 28, 56, 56 x 1, 98, 98 x
Brintellix film-coated tablets 15 mg are available in blister packs of 14, 28, 56, 56 x 1, 98, 98 x 1, 490 (5 x (98x1)) tablets and in tablet containers of 100 and 200 tablets.
Brintellix filmom obložene tablete 15 mg dostupne su u blister pakiranjima od 14, 28, 56, 56 x 1, 98, 98 x 1, 490 (5 x (98x1)) tableta te u spremnicima za tablete od 100 i 200 tableta.
Brintellix film-coated tablets 20 mg are available in blister packs of 14, 28, 56, 56x1, 98, 98x1, 126 (9x14), 490 (5x(98x1)) tablets and in tablet containers of 100, 200 tablets.
Brintellix filmom obložene tablete 20 mg dostupne su u blister pakiranjima od 14, 28, 56, 56 x 1, 98, 98 x 1, 126 (9x14), 490 (5x( 98x1)) tableta te u spremnicima za tablete od 100 i 200 tableta.
Brintellix film-coated tablets 5 mg are available in blister packs of 14, 28, 98, 56x1, 98x1, 126 (9x14) 490 (5x(98x1)) tablets and in tablet containers of 100 and 200 tablets.
Brintellix filmom obložene tablete 5 mg dostupne su u blister pakiranjima od 14, 28, 56x1, 98, 98x1, 126 (9x14), 490 (5x(98x1)) tableta te u spremnicima za tablete od 100 i 200 tableta.
Brintellix has been shown to reduce the broad range of depressive symptoms, including sadness, inner tension (feeling anxious), sleep, disturbances (reduced sleep), reduced appetite, difficulty in concentrating, feelings of worthlessness, loss of interest in favourite activities, feeling of being slowed down.
Pokazalo se da Brintellix smanjuje široki raspon depresivnih simptoma, uključujući tugu, unutarnju napetost (osjećaj tjeskobe), smetnje spavanja (smanjeno spavanje), smanjeni apetit, otežanu koncentraciju, osjećaj bezvrijednosti, gubitak interesa za omiljene aktivnosti, osjećaj usporenosti ili usporenost.
Brintellix has no or negligible influence on the ability to drive and use machines.
Brintellix ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
Brintellix is used to treat major depressive episodes in adults.
Brintellix se koristi za liječenje velikih depresivnih epizoda u odraslih.
Brintellix oral drops, solution, are available in 20 ml amber glass bottles.
Brintellix oralne kapi, otopina su dostupne u jantarnim staklenim bocama od 20 ml.
Brintellix should be used with caution in patients with a history of mania/hypomania and should be discontinued in any patient entering a manic phase.
Brintellix treba primjenjivati s oprezom u bolesnika s anamnezom manije/hipomanije te liječenje treba prekinuti u svakog bolesnika koji ulazi u maničnu fazu.
Brintellix should not be used during pregnancy unless the clinical condition of the woman requires treatment with vortioxetine.
Brintellix se ne smije primjenjivati tijekom trudnoće, osim ako kliničko stanje žene zahtijeva liječenje vortioksetinom.
Brintellix should not be used during pregnancy unless thedoctor says it is absolutely necessary.
Brintellix se ne smije primjenjivati tijekom trudnoče, osim ako liječnik ne kaže da je apsolutno nužno.
Brinzolamide
Brinzolamid
Brinzolamide + Brimonidine Meana
Brinzolamid + brimonidin Srednja vrijednosta
Brinzolamide and N-desethylbrinzolamide are the predominant components in the urine along with trace levels (<1%) of the N-desmethoxypropyl and O-desmethyl metabolites.
Brinzolamid i N-desetil-brinzolamid su predominantne sastavnice u urinu, zajedno s N- dezmetoksipropilnim i O-dezmetilnim metabolitima u tragovima (<1%).
Brinzolamide and timolol are absorbed systemically.
Brinzolamid i timolol se apsorbiraju sustavno.
Brinzolamide belongs to a group of medicines called ‘carbonic anhydrase inhibitors’ and brimonidine tartrate belongs to a group of medicines called ‘alpha-2 adrenergic receptor agonists’.
Brinzolamid pripada skupini lijekova koja se naziva“ inhibitori karboanhidraze“ i brimonidin tartarat pripada skupini lijekova koja se naziva „ agonisti alfa-2-adrenergičkih receptora“.
Brinzolamide is a potent inhibitor of human carbonic anhydrase II (CA-II), the predominant iso- enzyme in the eye.
Brinzolamid je potentni inhibitor ljudske karboanhidraze II (CA-II), predominantnog izoenzima u oku.
Brinzolamide is eliminated primarily by renal excretion (approximately 60%).
Brinzolamid se eliminira prvenstveno izlučivanjem putem bubrega (približno 60 %).
Brinzolamide is metabolized by hepatic cytochrome P450 isozymes, specifically CYP3A4, CYP2A6, CYP2B6, CYP2C8 and CYP2C9.
Brinzolamid se metabolizira putem jetrenih citokrom P450 izoenzima, posebno CYP3A4, CYP2A6, CYP2B6, CYP2C8 i CYP2C9.
Brinzolamide is moderately bound (about 60%) to human plasma proteins.
Brinzolamid se umjereno veže (oko 60 %) na proteine plazme kod ljudi.
Brinzolamide is sequestered in RBCs due to its high affinity binding to CA-II and to a lesser extent to CA-I.
Brinzolamid se sekvestrira u eritrocitima, zbog visokog afiniteta vezanja na CA-II i nešto slabijeg afiniteta vezanja na CA-I.
Brinzolamide was teratogenic in rats, but not rabbits, following systemic administration.
Brinzolamid je bio teratogen kod štakora, ali ne kod kunića, nakon sistemske primjene.
Bristol-Myers Squibb Company 6000 Thompson Road, East Syracuse New York 13057 – U.S.A.
Bristol-Myers Squibb Company 6000 Thompson Road, East Syracuse New York 13057 – SAD
Bristol-Myers Squibb Pharma EEIG Uxbridge Business Park - Sanderson Road Uxbridge UB8 1DH - United Kingdom
Bristol-Myers Squibb Pharma EEIG Uxbridge Business Park - Sanderson Road Uxbridge UB8 1DH - Ujedinjeno Kraljevstvo
Bristol-Myers Squibb Pharma EEIG Uxbridge Business Park - Sanderson Road Uxbridge UB8 1DH - United Kingdom
Bristol-Myers Squibb Pharma EEIG Uxbridge Business Park - Sanderson Road Uxbridge UB8 1DH – Ujedinjeno Kraljevstvo
Bristol-Myers Squibb S.R.L. Contrada Fontana del Ceraso 03012 Anagni (FR) - Italy
Bristol-Myers Squibb S.R.L. Contrada Fontana del Ceraso 03012 Anagni (FR) - Italija
Bristol-Myers Squibb S.R.L. Contrada Fontana del Ceraso I-03012 Anagni-Frosinone Italy
Bristol-Myers Squibb S.R.L. Contrada Fontana del Ceraso I-03012 Anagni-Frosinone Italija
Bristol-Myers Squibb S.r.l., Contrada Fontana del Ceraso, 03012 Anagni (FR), Italy
Bristol-Myers Squibb S.r.l., Contrada Fontana del Ceraso, 03012 Anagni (FR), Italija
Bristol-Myers Squibb/Pfizer EEIG, Bristol-Myers Squibb House, Uxbridge Business Park, Sanderson Road, Uxbridge, Middlesex UB8 1DH - United Kingdom
Bristol-Myers Squibb/Pfizer EEIG, Bristol-Myers Squibb House, Uxbridge Business Park, Sanderson Road, Uxbridge, Middlesex UB8 1DH - Velika Britanija
bRitonavir oral solution cRitonavir oral solution or capsule/tablet
b Ritonavir oralna otopina cRitonavir oralna otopina ili kapsule/tablete
Brittle and
ulceracije rožnice
Brittle or weak nails
krhki ili slabi nokti
Brivaracetam given 50 or 150 mg/day did not affect the AUC of midazolam (metabolised by CYP3A4).
Brivaracetam u dozi od 50 ili 150 mg/dan nije utjecao na AUC midazolama (koji se metabolizira putem enzima CYP3A4).
Brivaracetam may increase plasma concentrations of medicinal products metabolised by CYP2C19 (e.g. lanzoprazole, omeprazole, diazepam).
Brivaracetam može povisiti plazmatsku koncentraciju lijekova metaboliziranih s enzimom CYP2C19 (npr. lanzoprazola, omeprazola, diazepama).
Brivaracetam plasma concentrations may increase when coadministered with CYP2C19 strong inhibitors (e.g. fluconazole, fluvoxamine), but the risk of a clinically relevant CYP2C19-mediated inteaction is considered to be low.
Plazmatske koncentracije brivaracetama mogu se povećati pri njegovoj istodobnoj primjeni sa snažnim inhibitorima enzima CYP2C19 (npr. flukonazolom, fluvoksaminom), ali se rizik od klinički značajnih interakcija posredovanih enzimom CYP2C19 smatra niskim.
Brivaracetam was evaluated in these patients in short term open label pharmacokinetic study and an ongoing open-label extension study, in 152 subjects from 1 month to 16 years of age (see section 5.2).
Primjena brivaracetama u tih bolesnika ocjenjivala se u kratkoročnom otvorenom farmakokinetičkom ispitivanju i otvorenom nastavku ispitivanja koje je još u tijeku, u 152 ispitanika u dobi od 1 mjeseca do 16 godina (vidjeti dio 5.2).
Brivaracetam was evaluated in these patients in short term open-label pharmacokinetic study and an ongoing open-label extension study, in 152 subjects from 1 month to 16 years of age (see section 5.2).
Primjena brivaracetama u tih bolesnika ocjenjivala se u kratkoročnom otvorenom farmakokinetičkom ispitivanju i otvorenom nastavku ispitivanja koje je još u tijeku, u 152 ispitanika u dobi od 1 mjeseca do 16 godina (vidjeti dio 5.2).
Briviact 10 mg are white to off-white, round, film-coated tablets of 6.5 mm in diameter and debossed with ‘u10’ on one side.
Briviact 10 mg su bijele do bjelkaste, okrugle, filmom obložene tablete promjera 6,5 mm, s utisnutom oznakom ‘u 10’ na jednoj strani.
Briviact 10 mg/ml (Only for outer carton)
Briviact 10 mg/ml (samo za kutiju)
Briviact 10 mg/ml oral solution is slightly viscous, clear, colourless to yellowish liquid.
Briviact 10 mg/ml oralna otopina je blago viskozna, bistra, bezbojna do žućkasta tekućina.
Briviact 10 mg/ml solution for injection/infusion is a clear, colourless, sterile solution.
Briviact 10 mg/ml otopina za injekciju/infuziju je bistra, bezbojna, sterilna otopina.
Briviact 100 mg are green-grey, oval, film-coated tablets of 14.5 mm x 8.1 mm and debossed with ‘u100’ on one side.
Briviact 100 mg su zeleno-sive, ovalne, filmom obložene tablete dimenzija 14,5 mm x 8,1 mm, s utisnutom oznakom ‘u 100’ na jednoj strani.
Briviact 10mg/ml oral solution brivaracetam
Briviact 10 mg/ml oralna otopina brivaracetam
Briviact 10mg/ml solution for injection/infusion brivaracetam
Briviact 10 mg/ml otopina za injekciju/infuziju brivaracetam
Briviact 25 mg are grey, oval, film-coated tablets of 8.9 mm x 5.0 mm and debossed with ‘u25’ on one side.
Briviact 25 mg su sive, ovalne, filmom obložene tablete dimenzija 8,9 mm x 5,0 mm, s utisnutom oznakom ‘u 25’ na jednoj strani.
Briviact 50 mg are yellow, oval, film-coated tablets of 11.7 mm x 6.6 mm and debossed with ‘u50’ on one side.
Briviact 50 mg su žute, ovalne, filmom obložene tablete dimenzija 11,7 mm x 6,6 mm, s utisnutom oznakom ‘u 50’ na jednoj strani.
Briviact 75 mg are purple, oval, film-coated tablets of 13.0 mm x 7.3 mm and debossed with ‘u75’ on one side.
Briviact 75 mg su ljubičaste, ovalne, filmom obložene tablete dimenzija 13,0 mm x 7,3 mm, s utisnutom oznakom ‘u 75’ na jednoj strani.
Briviact can be given by injection or by infusion (drip) into a vein if it cannot be given by mouth.
Briviact se može davati intravenskom injekcijom ili infuzijom (drip) ako se ne može davati kroz usta.
Briviact is a long term treatment – keep taking Briviact until your doctor tells you to stop.
Briviact je lijek za dugoročno liječenje – nastavite ga uzimati dok Vam liječnik ne kaže da prestanete.
Briviact is an epilepsy medicine used as an add-on to other epilepsy medicines to treat partial-onset seizures (epileptic fits starting in one specific part of the brain).
Briviact je lijek za epilepsiju koji se upotrebljava kao dodatak drugim lijekovima za epilepsiju u liječenju parcijalnih napadaja (epileptičnih napadaja koji započinju u određenom dijelu mozga).
Briviact is available as tablets (10, 25, 50, 75 and 100 mg), an oral solution (10 mg/ml) and a solution for injection or infusion (drip) into a vein (10 mg/ml).
Briviact je dostupan u obliku tableta (od 10, 25, 50, 75 i 100 mg), oralne otopine (10 mg/ml) i otopine za intravensku injekciju ili infuziju (drip) (10 mg/ml).
Briviact is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy.
Briviact je indiciran kao dodatna terapija u liječenju parcijalnih napadaja sa sekundarnom generalizacijom ili bez nje u odraslih bolesnika i adolescenata od navršenih 16 godina koji boluju od epilepsije.
Briviact is more effective than placebo (a dummy treatment) at reducing seizures.
Briviact je učinkovitiji od placeba (prividnog liječenja) u smanjivanju napadaja.
Briviact is not recommended for use in children and young people under 16 years of age.
Primjena lijeka Briviact ne preporučuje se u djece i osoba mlađih od 16 godina.
Briviact is used in adults and adolescents from 16 years of age to treat a type of epilepsy characterized by the occurrence of partial seizures with or without secondary generalisation’.
Briviact se koristi u odraslih i adolescenata u dobi od navršenih 16 godina za liječenje jedne vrste epilepsije karakerizirane pojavom parcijalnih napadaja uz sekundarnu generalizaciju ili bez nje.
Briviact is used in adults and adolescents from 16 years of age to treat a type of epilepsy characterized by the occurrence of partial seizures with or without secondary generalization’.
Briviact se koristi u odraslih i adolescenata u dobi od navršenih 16 godina za liječenje jedne vrste epilepsije karakterizirane pojavom ‘parcijalnih napadaja uz sekundarnu generalizaciju ili bez nje’.
Briviact is used together with other medicines for epilepsy.
Briviact se primjenjuje zajedno s lijekovima za liječenje epilepsije.
Briviact may be diluted before it is injected by your doctor or nurse.
Prije injekcije, liječnik ili medicinska sestra mogu razrijediti Briviact.
Briviact may be diluted with the following solutions: sodium chloride 9 mg/ml (0.9 %), glucose 50 mg/ml (5 %) solution for injection or lactated Ringer’s solution.
Briviact se može razrijediti sljedećim otopinama: otopinom natrijeva klorida za injekcije od 9 mg/ml (0,9%), otopinom glukoze za injekcije od 50 mg/ml (5%) ili otopinom Ringerova laktata.
Briviact must not be used in patients who are hypersensitive (allergic) to brivaracetam, to other pyrrolidone derivatives (substances that are chemically similar to brivaracetam), or to any of the other ingredients.
Briviact se ne smije primjenjivati u bolesnika koji su preosjetljivi (alergični) na brivaracetam, na druge derivate pirolidona (tvari koje su kemijski slične brivaracetamu) ili na bilo koji drugi sastojak lijeka.
Briviact oral solution contains methyl parahydroxybenzoate, sodium and sorbitol
Briviact oralna otopina sadrži metilparahidroksibenzoat, natrij i sorbitol
Briviact oral solution contains: methyl parahydroxybenzoate (E218) - this may cause allergic reactions (possibly delayed).
Briviact oralna otopina sadrži: metilparahidroksibenzoat (E218) – može uzrokovati alergijske reakcije (koje mogu biti odgođene).
Briviact solution for injection/infusion is used for a short amount of time when you cannot take Briviact orally.
Briviact otopina za injekciju/infuziju koristi se tijekom kraćih vremenskih razdoblja kada ne možete uzimati Briviact kroz usta.
Briviact tablets are packaged in blister packs supplied in cardboard boxes containing either 14, 56 or 14 x 1 or 100 x 1 film-coated tablets or in multipacks containing 168 (3 packs of 56) film-coated tablets.
Briviact tablete zapakirane su u blister pakiranja uložena u kutije koje sadrže 14, 56 ili 14 x 1 ili 100 x 1 filmom obloženu tabletu ili višestruka pakiranja koja sadrže 168 (3 pakiranja od 56) filmom obloženih tableta.
Briviact with alcohol
Briviact s alkoholom
Broadline can also be used to prevent heartworm disease for one month.
Broadline se također može koristiti za sprječavanje bolesti srčanog crva tijekom mjesec dana.
Broadline is a veterinary medicine that contains four active substances: fipronil, (S)-methoprene, eprinomectin and praziquantel.
Broadline je veterinarsko-medicinski proizvod koji sadrži četiri djelatne tvari: fipronil, (S)-metopren, eprinomektin i prazikvantel.
BROADLINE is not intended for use in dogs.
BROADLINE nije namijenjen psima.
Broadline is used to treat cats with, or at risk of, mixed infestations by tapeworms, roundworms and external parasites (fleas, ticks and a burrowing mite called Notoedres cati).
Broadline se koristi za liječenje mačaka u slučaju rizika ili oboljelih od kombinirane infestacije trakavicama, oblićima i ektoparazitima (buhe, krpelji i šugarac pod nazivom Notoedres cati).
Broadline must not be used in sick or recovering animals.
Broadline se ne smije koristiti u bolesnih životinja ili životinja koje se oporavljaju.
BROADLINE spot- on solution
otopina za nakapavanje